Human Liver Model Market Report 2026

The human liver model market size has grown rapidly in recent years. It will grow from $2.62 billion in 2025 to $2.98 billion in 2026 at a compound annual growth rate (CAGR) of 13.5%. The growth in the historic period can be attributed to increasing drug attrition due to liver toxicity, limitations of traditional animal models, growth of pharmaceutical research and development activities, early adoption of 2D liver cell culture models, rising focus on drug safety evaluation.

The human liver model market size is expected to see rapid growth in the next few years. It will grow to $5.02 billion in 2030 at a compound annual growth rate (CAGR) of 14%. The growth in the forecast period can be attributed to increasing demand for precision toxicology models, expansion of organ-on-chip technologies, growing regulatory focus on reducing animal testing, rising investment in advanced in vitro research tools, increasing use of human-relevant models in early drug development. Major trends in the forecast period include increasing adoption of advanced in vitro liver models for toxicity testing, growing use of liver organoids in drug discovery pipelines, rising preference for human-relevant models over animal testing, expansion of liver-on-a-chip applications in preclinical research, increasing demand for predictive hepatotoxicity assessment tools.

The growing number of clinical trials is expected to drive the human liver model market in the coming years. Clinical trials are research studies conducted to evaluate the safety and efficacy of medical interventions, treatments, or drugs in humans. Human liver models are used in these trials to simulate and study drug metabolism and hepatotoxicity, supporting pharmaceutical development. For example, in December 2024, the Association of the British Pharmaceutical Industry (ABPI), a UK-based organization, reported that the total number of clinical trials initiated in the UK increased from 411 in 2022 to 426 in 2023. Thus, the rise in clinical trials is contributing to the growth of the human liver model market.

Key companies in the human liver model market are focusing on developing advanced systems, such as single-organ higher throughput (HT) platforms, to promote adoption of predictive human liver models and gain a competitive edge. Single-organ HT systems are designed for scalable, cost-effective drug discovery, addressing obstacles to broader use of predictive liver models. For instance, in February 2023, CN Bio, a UK-based organ-on-a-chip company, launched PhysioMimix with Liver-48 plate, a single-organ HT system that miniaturizes the human liver model for larger-scale comparative studies on drug disposition, efficacy, and safety. Applications include predicting drug-induced liver injury and assessing drug metabolism, offering a scalable and cost-effective solution for researchers.

In April 2023, AnaBios Corporation, a biotechnology research company, acquired Cell Systems Inc. for an undisclosed amount. This acquisition aims to strengthen AnaBios’ drug discovery capabilities by integrating Cell Systems’ advanced cell-based technologies, enhancing its portfolio of human-relevant models to allow more accurate predictions of drug efficacy and safety. Cell Systems is a US-based biotechnology research company.

Major companies operating in the human liver model market are Corning Incorporated, EISCO Scientific LLC, BioIVT LLC, Cyprotex plc, Emulate Inc., Cellink AB, Nortis Inc., InSphero AG, CN Bio Innovations Ltd., TissUse GmbH, HemoShear Therapeutics Inc., Cyfuse Biomedical, MIMETAS BV, Biopredic International Sarl, ZenBio, Hurel Corporation, Regenovo, Pandorum, Organovo Holdings Inc., BICO Group, Hepregen Corporation, Kirkstall Ltd., HepaLife Technologies Inc., Cellaïon SA.

North America was the largest region in the human liver model market in 2025. The regions covered in the human liver model market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the human liver model market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the human liver model market by increasing the cost of imported laboratory equipment, microfluidic components, bioprinting systems, and specialized reagents required for advanced liver model development. These effects are most evident in liver-on-a-chip and 3D bioprinting segments and in regions such as North America and Europe that rely on global life sciences supply chains. Higher input costs may slow adoption among smaller research organizations; however, tariffs are also encouraging local manufacturing of research tools, regional sourcing strategies, and greater investment in domestic biotechnology infrastructure, supporting long-term market resilience.

The human liver model market research report is one of a series of new reports that provides human liver model market statistics, including human liver model industry global market size, regional shares, competitors with a human liver model market share, detailed human liver model market segments, market trends and opportunities, and any further data you may need to thrive in the human liver model industry. This human liver model market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The human liver model refers to a representation of the dual-lobed human liver, which is primarily responsible for filtering blood from the digestive tract. It is used to assess and demonstrate the toxic effects of drug candidates on the liver.

The main product types of human liver models include liver organoids, liver-on-a-chip systems, 2D models, animal models, and 3D bioprinting. Liver organoids are three-dimensional structures derived from stem cells that self-organize through processes similar to those occurring in vivo. Key applications of these models include educational purposes, drug discovery, and other research activities. They are primarily used by research institutes, pharmaceutical companies, and related organizations.

The human liver model market consists of sales of 3B scientific liver and prime baker fiber liver model. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.